The fasting lipid profile assesses total cholesterol and total triglycerides, in addition to the high and low density lipoprotein cholesterol fractions, from which ratios may be derived. A patient’s lipid status is an independent modifier of cardiovascular disease pathology. Its subsequent targeting, by pharmacological or dietary means, lowers the risk for developing such diseases.
Family history of cardiovascular or other thrombotic events Diagnosis and monitoring of hyperlipidaemia Monitoring of high-risk groups, eg. hypertensive, obese, diabetics, etc.
SST (gold top)
Non-HDL cholesterol (total chol minus HDL chol) is recommended for CVD risk prediction; fasting samples are not required for this.
Non-HDL cholesterol targets for patients treated for CVD risk reduction are 40 % reduction from baseline (NICE CG181, 2014) or <2.5 mmol/L (JBS3. Heart 2014;100:ii1)
The JBS3 CVD risk estimator is at http://www.jbs3risk.com/JBS3Risk.swf
Paediatric comments re Lipids
Total Cholesterol <4.4 mmol/L acceptable, >5.2 mmol/L high
LDL Cholesterol <2.8 mmol/L acceptable, >3.4 mmol/L high